Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SILIUS: Sorafenib vs Sorafenib + HAIC in Advanced HCC
NCT01214343Phase 3Unknown
- Sponsor
- Ministry of Health, Labour and Welfare
- Start
- Oct 2010
- Primary completion
- Sep 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cisplatin and fluorouracil in hepatocellular carcinoma (HCC) (2 arms), sponsored by Ministry of Health, Labour and Welfare. Primary endpoint: Overall Survival. Status: unknown.
02
Drugs
cisplatinfluorouracil
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01214343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01214343.